You're reading the free version. Trader adds the live tape and alerts.
Start tracking
KLRS Award Disclosure
Bayko Liisa Ann · SEC Form 4 · Filed Jul 20, 2026
Award
Calculated transaction value
$0
Bayko Liisa Ann Chief Financial Officer
KLRS
Transaction date
Jul 20, 2026
Public filing date
Jul 20, 2026
Filing lag
Filed same day
KLRS daily price context
No linked price history
This asset is not matched to a market-data symbol.
Source details
- Reported owner
- Not disclosed
- Source asset code
- Derivative
- Security
- Stock Option (Right to Buy) on Common Stock
- Quantity / price
- 220,000 shares @ $0
- SEC ownership
- Direct
- Transaction code
- A
- Form
- 4
- Filing identifier
- 0001193125-26-309047
Filing cohort
Transactions in this filing
Showing 1 of 1
Trades
1
Issuers
1
Estimated value
$0
Buys / sales
0 / 0
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Kalaris Therapeutics, Inc. KLRS Current | Award | Jul 20, 2026 | $0 |